How To Compare Warfarin To Dabigatran
|
|
- Shanna Kelley
- 3 years ago
- Views:
Transcription
1 Page 1 WOMEN AT RISK Anticoagulation Issues In Atrial Fibrillation WOMEN AT RISK Anticoagulation Issues In Atrial Fibrillation J E A N N A P P I, P H A R M. D., F C C P, B C P S Accreditation: Pharmacists: L01-P Nurses: N-722 CE Credits: 1.0 contact hour Target Audience: Pharmacists & Nurses This webcast has been supported by an educational grant from Boehringer Ingelheim Program Overview: This program will provide a brief overview of the pathophysiology, signs and symptoms of heart failure. The pharmacologic basis for the commonly used drugs used to manage patients with heart failure will be discussed. The ACC/AHA guidelines as well as the EMPHASIS-HF trail will be reviewed Objectives: Identify the under-recognized risk of strokes in women diagnosed with atrial fibrillation, and the associated morbidity, mortality, and cost burdens Provide an update on the efficacy, safety, and role of the available treatments for anticoagulation therapy in atrial fibrillation Outline the compliance communication strategies between pharmacists and their patients about the benefits and risks of anticoagulation therapy, especially with women. PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education Legal Disclaimer: The material presented here does not necessarily reflect the views of Pharmaceutical Education Consultants (PharmCon) or the companies that support educational programming. A qualified healthcare professional should always be consulted before using any therapeutic product discussed. Participants should verify all information and data before treating patients or employing any therapies described in this educational activity. This webcast has been supported by an educational grant from Boehringer Ingelheim 2 WOMEN AT RISK Anticoagulation Issues In Atrial Fibrillation Learning Objectives Speaker: Dr. Jean Nappi received her BS in Pharmacy from the State University of NY at Buffalo. She completed her Doctor of Pharmacy degree and residency in internal medicine from the University of Texas at Austin / UT Health Science Center at San Antonio. Dr. Nappi has been on the faculty at the Universities of Wisconsin, Utah, and Houston prior to her current position. She is now Professor of Clinical Pharmacy and Outcome Sciences in the South Carolina College of Pharmacy-MUSC Campus and Professor of Medicine (Cardiology) at the Medical University of South Carolina. Speaker Disclosure: Dr. Nappi has no actual or potential conflicts of interest in relation to this program This webcast has been supported by an educational grant from Boehringer Ingelheim PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education Legal Disclaimer: The material presented here does not necessarily reflect the views of Pharmaceutical Education Consultants (PharmCon) or the companies that support educational programming. A qualified healthcare professional should always be consulted before using any therapeutic product discussed. Participants should verify all information and data before treating patients or employing any therapies described in this educational activity. 3 At the completion of this activity, the participant will be able to: 1. Identify the under-recognized risk of strokes in women diagnosed with atrial fibrillation, and the associated morbidity, mortality, and cost burdens. 2. Provide an update on the efficacy, safety, and role of available treatments for anticoagulation therapy in atrial fibrillation. 3. Outline compliance communication strategies between pharmacists and their patients about the benefits and risks of anticoagulation therapy, especially with women. 4
2 Page 2 Atrial Fibrillation Prevalence of Stroke by Age and Gender Atrial fibrillation is a very common arrhythmia The lifetime risk for developing AF is 1 in 4 for both men and women Atrial fibrillation is a powerful risk factor stroke 5 fold increase in risk for stroke in patients with AF Strokes due to AF increases with age (~24% at age 80-89) Heart Disease and Stroke Statistics 2012 Update 5 Heart Disease and Stroke Statistics 2012 Update 6 Gender Differences In the Canadian Registry of Atrial Fibrillation compared to men, women were older than men at presentation (65 vs 60 yrs) had higher heart rates (126 vs 119) and more symptomatic older women were less likely to receive warfarin than older men 3.35 times more likely to have a major bleed while receiving warfarin Gender Differences Risk of TE and/or ischemic stroke in women with AF compared to men Study N (% women) Risk Randomized AF Investigators 3,432 (34) 1.2 ATRIA 13,559 (43) 1.5 SPAF 2,012 (28) 1.6 Observational Framingham 2,844(48) 1.92 Euro Heart Study 5,333 (42) 1.83 Copenhagen 29,310 (40) 2.6 Women more likely to have stroke when not taking warfarin compared to men. They were not more likely to have a major bleed when INR was controlled. Humphries et al. Circulation 2001;103: Lane et al. Thromb Haemost 2009;101:
3 Page 3 CHADS 2 Score CHA 2 Ds 2 VASc Score Cardiac failure: Hypertension: Age> 75: Diabetes: Stroke or TIA: 1 pt 1 pt 1 pt 1 pt 2 pts Congestive heart failure 1 Congestive heart failure/lvd 1 Hypertension 1 Hypertension 1 Age 75 years 1 Age 75 years 2 Diabetes mellitus 1 Diabetes mellitus 1 Stroke/TIA/ TE 2 Stroke/TIA/ TE 2 Maximum score 6 Vascular disease (MI, PAD, aortic plaque) 1 ACC/AHA/HRS Age years 1 Sex category (female gender) 1 Maximum score 9 European Society of Cardiology Aspirin 0 Aspirin or no antithrombotic therapy (preferred) Aspirin or anticoagulant 1 Aspirin or oral anticoagulant (preferred) Oral anticoagulant 2 Oral anticoagulant Eur Heart J 2010;31: Circulation 2011; 123:e269-e Cost of Stroke In 2008, the direct and indirect cost of stroke was $34.3 billion Direct medical costs $18.8 billion Mean lifetime costs for ischemic stroke is $140,048 Anticoagulation In Atrial Fibrillation One in six strokes is cardioembolic in origin RE-LY vs warfarin Rocket-AF Rivaroxaban vs warfarin Aristotle Apixaban vs warfarin Heart Disease and Stroke Statistics 2012 Update 11 12
4 Page 4 W Factor IX Rivaroxaban Apixaban MECHANISMS OF ACTION Factor IXa W Factor X Factor Xa Prothrombin (Factor II) W W Factor VII Factor VIIa Distribution Rivaroxaban Apixaban Vitamin K Antagonist Direct thrombin inhibitor Factor Xa inhibitor Factor Xa inhibitor Affects the synthesis of Vitamin K dependent factors ( II, VII, IX, X ) 99% bound Vd = 0.14 L/kg Requires conversion to active form by a serum esterase, reversible 35% bound Vd = L Half-life hours hours 34 hours in ESRD Elimination Drug interactions Metabolized via CYP 2C9, 2C19, 2C8, 2C18, 1A2, 3A4 YES Metabolized to active metabolites; 80% excreted renally P-gp inducers AUC (rifampin), P-gp inhibitors Dose-dependent inhibition of Factor Xa 92-95% bound Vd = 50 L 5-9 hours in elderly 50% metabolized, 36% excreted renally P-gp and strong CYP3A4 inhibitors/inducers Direct acting reversible Factor Xa inhibitor 87% bound 9-14 hours Metabolized via CYP3A4 and 3A5 25% excreted renally CYP3A4 inhibitors/inducers? Monitoring PT/INR None (ECT Ecarin Clotting Time used) Clin Pharmacokinet. 2009;48(1):1-22 Fibrinogen Thrombin (Factor IIa) Fibrin Antidote Vitamin K, FFP Dialysis, antifibrinolytics, rfviia? Other S entantiomer 2-5x more potent, 2C9, VKOR polymorphisms Keep in original container, do not open capsules Dosing Highly individualized 150 mg bid (CrCl>30) 75 mg bid (CrCl 15-30) PCC (prothrombin complex concentrate) Japanese and elderly: 50% higher exposure 20 mg daily 15 mg (CrCl 15-50) 5 mg bid (2.5 mg bid) Anticoagulation In Atrial Fibrillation versus warfarin in patients with atrial fibrillation (RE-LY) Connolly SJ et al New England Journal of Medicine 2009;361: RE-LY THE RANDOMIZED EVALUATION OF LONG-TERM ANTICOAGULATION THERAPY Randomized to adjusted-dose warfarin (open-label) or fixed dose dabigatran 110 mg or 150 mg BID (blinded) Non-inferiority trial of >18,000 patients Sponsored by Boehringer Ingelheim Patient enrollment: December 05-December 07 Final follow up: December 08-March 09 Population Health Research Institute of Canada independently managed the database and performed the primary data analysis 15 16
5 Page 5 RE-LY ENDPOINTS RE-LY POPULATION Primary- stroke or systemic embolism Safety- major hemorrhage Secondary- stroke, systemic embolism, and death Other MI, PE, TIA, hospitalization Primary net clinical benefit (composite of stroke, systemic embolism, PE, MI, death or major hemorrhage) Included Atrial fibrillation at screening or within last 6 months and one of the following: Previous stroke, EF < 40% NYHA II or higher Age >75 Age DM, HTN, CAD Excluded Severe valvular disease Stroke within 14 days Severe stroke within 6 months Risk for hemorrhage Creatinine clearance <30 ml/min Active liver disease Pregnancy RE-LY DEMOGRAPHICS 18,113 patients enrolled, well-matched Mean age 71.5 years, 35% female One-third in each group had persistent, paroxysmal and permanent AF 20% had previous stroke or TIA 32% had HF, 23% DM, 79% HTN Mean CHADs score was % were on vitamin K antagonist at baseline RE-LY RESULTS Primary End Point - stroke or systemic embolism 110 mg bid 150 mg bid Primary End Point % per year Relative risk for 1 End Point compared to warfarin 0.91 ( ) 0.66 ( ) Hemorrhagic stroke % per year Relative risk for hemorrhagic stroke compared to warfarin 0.31 ( ) 0.26 ( ) P value < both doses non-inferior higher dose superior <
6 Page 6 RE-LY SECONDARY OUTCOMES 110 mg bid 150 mg bid Death from any cause % per year Relative risk for death compared to warfarin Myocardial infarction % per year Relative risk for myocardial infarction 0.91 ( ) P= ( ) P= ( ) P= ( ) P= RE-LY ADVERSE EVENTS 110 mg bid 150 mg bid Major bleeding % per year Relative risk for: Life threatening bleed Intracranial bleed Major or minor bleed Net clinical benefit % per year (vascular events, major bleeding, death) 0.68 ( ) 0.31 ( ) 0.78 ( ) 7.09 RR = 0.92 ( ) P= ( ) 0.40 ( ) 0.91 ( ) 6.91 RR = 0.91 ( ) P= RE-LY Anticoagulation In Atrial Fibrillation Other noteworthy points More discontinuations in dabigatran groups (21% vs 17% at 2 years) Two fold increase in dyspepsia (11.5%) Increase in MI Also seen with ximelagatran INRs were therapeutic 64% of time Recommended dose CrCl >30 ml/min, dose dabigatran 150 mg twice daily, CrCl ml/min, dose dabigatran 75 mg twice daily No recommendations for patients with a CrCl <15 ml/min or on dialysis Drug interactions P-glycoprotein inhibitors (verapamil, amiodarone, quinidine) raise dabigatran serum concentrations but do not require dose adjustment P-glycoprotein inducers (rifampin) reduce dabigatran serum concentrations and should be avoided 23 Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (Rocket AF) Patel MR et al New England Journal of Medicine 2011;365:
7 Page 7 ROCKET AF ROCKET-AF ENDPOINTS Randomized, double-blind, double dummy non-inferiority trial of rivaroxaban vs warfarin Sponsored by Johnson & Johnson and Bayer ~14,000 patients with atrial fibrillation 2 risk factors (CHF, HTN, age >75, DM) or Stroke, TIA or systemic embolism Rivaroxaban 20 mg daily 15 mg daily for Cr Cl ml/min adjusted to INR 2-3 Primary endpoint: stroke or non-cns embolism 25 Primary Efficacy Endpoint Composite of stroke and systemic embolism Primary Safety Endpoint Composite of major and non-major bleeding events Secondary Endpoints Composite of stroke, systemic embolism, or death from cardiovascular causes Composite of stroke, systemic embolism, death from cardiovascular causes, or MI Individual components of composite endpoints New Engl J Med (10): ROCKET-AF POPULATION ROCKET AF DEMOGRAPHICS Included Nonvalvular atrial fibrillation Moderate-to-high risk of stroke History of stroke or TIA History of systemic embolism At least 2 of the following: Heart failure or LVEF < 35% Hypertension Age 75 years Diabetes Mellitus Excluded Significant mitral valve stenosis Prosthetic heart valve Creatinine Clearance <30 ml/min Increased bleeding risk ASA > 100 mg daily Stroke within past 14 days Or severe, disabling stroke within past 3 months Uncontrolled HTN ( 180/100) Pregnancy 14,171 patients enrolled, well-matched Median age 73 years, 40% female 55% had previous stroke, TIA, embolism 62% had HF, 40% DM, 90% HTN Mean CHADs score was 3.5 (median = 3.0) 62% prior vitamin K antagonist use New Engl J Med (10):
8 Page 8 ROCKET AF RESULTS Primary End Point - stroke or systemic embolism Rivaroxaban Hazard ratio (95% CI) P value ROCKET AF ADVERSE BLEEDING EVENTS Rivaroxaban (n=7111) Events # (%) Rate #/100 pt-yr Events # (%) (n=7125) Rate #/100 pt-yr Hazard ratio (95% CI) P value On treatment per protocol ITT After Discont ( ) ( ) 1.1 <0.001 for noninferiority <0.001 for noninferiority 0.12 for superiority 0.58 Major & non-major clinically relevant bleeding Intracranial hemorrhage Non-major clinically relevant bleeding 1475 (20.7) 55 (0.8) 1185 (16.7) (20.3) (1.2) Any major bleeding More in Hgb >2 and need for transfusion (16.2) More critical and fatal bleeding ( ) ( ) ( ) 1.04 ( ) Event rate expressed as percent / year Other noteworthy points ROCKET AF INRs were therapeutic 55% of time Less than 50% achieved the TTR threshold of >58-60% The efficacy of rivaroxaban, as compared to warfarin, was as favorable in centers with the best INR control as in those with poorer control 31 Pros ROCKET AF SUMMARY Appears to be a reasonable alternative to warfarin with easy dosing No INR monitoring Cons By intention to treat analysis, rivaroxaban was non-inferior to warfarin, but did not achieve superiority despite rather poor achievement of target INR 32
9 Page 9 Anticoagulation In Atrial Fibrillation Apixaban versus warfarin in patients with atrial fibrillation ARISTOTLE Granger CB et al New England Journal of Medicine 2011;365: ARISTOTLE Randomized, double-blind, double-dummy trial of apixaban 5 mg bid to adjusted warfarin Sponsored by Bristol-MyersSquibb and Pfizer ~18,000 patients with atrial fibrillation and 1 risk factor of stroke Apixaban 5 mg bid 2.5 mg bid for: age 80 yo, wgt 60 kg, or serum cr >1.5 mg/dl adjusted to INR 2-3 Primary endpoint: stroke or non-cns embolism ARISTOTLE ENDPOINTS Primary Efficacy Endpoint Composite of stroke and systemic embolism (noninferiority) Primary Safety Endpoint Major bleeding events (ISTH criteria) Secondary Endpoints Superiority relative to the primary outcome Superiority relative to warfarin in rates of major bleeding Death from any cause N Engl J Med (10): ARISTOTLE POPULATION Included Nonvalvular atrial fibrillation 2 or more episodes of AF within last 12 months 1 additional risk factor Age 75 Previous stroke, TIA, systemic embolism Symptomatic HF or EF 40% DM HTN Excluded Moderate-severe mitral stenosis Prosthetic heart valve Stroke within previous 7 days Creatinine 2.5 mg/dl Creatinine Cl < 25 ml/min Increased bleeding risk ASA > 165 mg daily Dual antiplatelet therapy New Engl J Med (10):
10 Page 10 ARISTOTLE DEMOGRAPHICS ARISTOTLE RESULTS 18,201 patients enrolled, well-matched Median age 70 years, 35% female 19% had previous stroke, TIA, embolism 35% had HF, 25% DM, 88% HTN Mean CHADS score End Point stroke/systemic embolism Stroke Ischemic,uncertain Hemorrhagic Systemic embolism Apixaban (n=9120) (n=9081) Hazard ratio (95% CI) ( ) ( ) 0.92 ( ) 0.51 ( ) 0.87 ( ) P value < Event rate expressed as percent / year 38 ARISTOTLE SECONDARY EVENTS ARISTOTLE ADVERSE BLEEDING EVENTS Apixaban (n=9120) (n=9081) Hazard ratio (95% CI) P value Apixaban (n=9120) (n=9081) Hazard ratio (95% CI) P value Rate Rate Rate Rate Death from any cause ( ) Stroke, embolism, or death ( ) ISTH Major bleeding ( ) Intracranial hemorrhage ( ) <0.001 <0.001 Myocardial infarction ( ) Stroke, embolism, MI, or death ( ) GUSTO severe bleeding ( Any bleeding ( ) <0.001 <0.001 Event rate expressed as percent / year 39 Event rate expressed as percent / year 40
11 Page 11 ARISTOTLE Pros 21% RRR in stroke or systemic embolism 31% RRR in major bleeding 11% RRR in death No monitoring TTR 66% Cons Sponsor on steering committee and authorship BID vs daily dosing 41 Trial RE-LY ROCKET-AF ARISTOTLE Drug Trial design, randomized 18,113 (3 arms) 14,264 18, mg bid 110 mg bid Open label Rivaroxaban 20 mg (15 mg) daily Double blind, double dummy Apixaban 5 mg (2.5 mg) bid Double blind, double dummy Mean Age (yrs) Male 63.6% 60.1% 65.3% Previous CVA 20% 54.7% 18.9% CHADS score % 0-1 % 2 % 3 Efficacy: % vs warfarin (CVA or Systemic Embolism) % 35% 33% 1.11 v p<0.001 NNT = 172 Major Bleeding % 3.11 vs 3.36 p=0.31 Conclusion vs. warfarin Superior efficacy for high dose, similar bleeding 3.5 0% 13% 87% 2.1 vs 2.4 p<0.001 non-inferiority p=0.12 superiority 3.4 vs 3.6 p=0.58 Non-inferior on efficacy and safety measures (ITT) % 36% 30% 1.27 vs 1.60 p < NNT = vs 3.09 p<0.001 Superior efficacy, less major bleeding, lower mortality Summary What Next? All 3 agents reduce hemorrhagic stroke vs warfarin High dose superior to warfarin, similar bleeding Reduces ischemic and hemorrhage stroke Rivaroxaban Non-inferior to warfarin (some sub-analysis showed superiority) Higher risk population Apixaban Compared to aspirin (AVERROES), superior efficacy, similar bleeding Superior to warfarin, less bleeding, reduced mortality Cost-effectiveness? What is the role of TTR (time in therapeutic range) for warfarin Patient selection Renal insufficiency Elderly Dose adjustment Concomitant CAD and antiplatelet agents Rebound with drug discontinuation? Drug interactions 43 44
12 Page 12 (Coumadin) VKA Many drug-drug interactions, especially amiodarone Drug-food interactions INR for routine monitoring Use in Atrial Fibrillation (Pradaxa) DTI Consider dose reduction to 75 mg bid if dronedarone or ketoconazole used in patients with Cr Cl Avoid with rifampin. Do not open the capsules Routine monitoring not needed Rivaroxaban (Xarelto) Xa Inhibitor Avoid with strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) and inducers (carbamazepine, phenytoin, rifampin, St Johns wort) Routine monitoring not needed Vitamin K is an antidote No antidote for bleeding Prothrombin complex concentrate has been used No dose adjustment with renal insufficiency 150 mg bid if Cr Cl >30 75 mg bid if CrCl Dyspepsia is common 20 mg daily if Cr Cl>50 15 mg daily if CrCl Patient Counseling Female gender has been identified in some studies as a risk factor for bleeding with anticoagulation. The benefit of anticoagulation outweighs the risk in the vast majority of cases. Women more likely to have stroke when not taking warfarin compared to men. Inform the patient to watch for signs and symptoms of bleeding but also subtle signs of blood loss (fatigue, orthostatic hypotension) 46 Notes Notes 47 48
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationAnticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationNew Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011
New Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011 Warfarin Decreases stroke risk by 60-70% Superior to ASA and ASA plus clopidogrel
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationNon- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationNovel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationAF, Stroke Risk and New Anticoagulants
Carmarthen Cardiac Update Course AF, Stroke Risk and New Anticoagulants Dr Hamsaraj Shetty, B.Sc, FRCP (London & Edinburgh) Consultant Physician & Honorary Senior Lecturer University Hospital of Wales,Cardiff
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationManagement of atrial fibrillation. Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD
Management of atrial fibrillation Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD Antithrombotic therapy in atrial fibrillation Satchana Pumprueg, MD AF has serious consequences Independent
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationAtrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller
Atrial Fibrillation: Stroke and Thromboprophylaxis Derek Waller Atrial Fibrillation in the Elderly: Risk of Stroke Framingham study AGE 50-59 60-69 70-79 80-89 Prevalence of AF % Attributable Risk of AF
More informationEfficacy in Hip Arthroplasty. Efficacy in Knee Arthroplasty. Adverse Effects. Drug Interactions
Objectives Just for the RECORD: Rivaroxaban joins the US Anticoagulation Arsenal Anne P. Spencer, PharmD, FCCP, BCPS (AQ Cardiology) Cardiovascular Care Pharmacy Specialist Roper Saint Francis Healthcare
More informationCardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationNOAC S For Stroke Prevention in. Atrial Fibrillation. Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health
NOAC S For Stroke Prevention in Atrial Fibrillation Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health New Oral Anti Coagulant Formal Definition: Atrial Fibrillation
More information22-Oct-14. Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants. Atrial Fibrillation. AF as an embolic risk factor
Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants Dr Scott McKenzie BSc MBBS FRACP FCSANZ Cardiologist, Vascular Physician, Telehealth Specialist, Advanced Heart
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationNew Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Jafna L. Cox, MD, FRCPC, FACC
New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Jafna L. Cox, MD, FRCPC, FACC Heart and Stroke Foundation of Nova Scotia Endowed Chair in Cardiovascular Outcomes Research Director
More informationOral Anticoagulation in Older Persons The Next Generation
Oral Anticoagulation in Older Persons The Next Generation Luis Viana B.Sc. Phm., Pharm D (candidate), M.Ed., ACPR, CGP Clinical Consultant Pharmacist, Medical Pharmacies Group Limited Adjunct Clinical
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationCCPN SPAF Tool. www.ccpn.ca STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF): POCKET REFERENCE
SEPTEMBER 2012 CCPN SPAF Tool STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF): POCKET REFERENCE Approximately 20% of all strokes are attributable to Atrial Fibrillation (AF). 1 Of these, 20% will result
More informationXarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason
Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical
More information48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationNew Anticoagulants- Dabigatran/Rivaroxaban
New Anticoagulants- Dabigatran/Rivaroxaban JOHN NOVIASKY, PHARMD, BCPS, FNYSCHP CGH AT UPSTATE UNIVERSITY HOSPITAL SYRACUSE NY Objectives Describe the risks and benefits of dabigatran therapy Describe
More informationPrevention of thrombo - embolic complications
Update on atrial fibrillation Prevention of thrombo - embolic complications Felicita Andreotti Dept of Cardiovascular Science Catholic University, Rome, IT Consultant or speaker in past 2 years for Amgen,
More informationrivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (756/12) Bayer PLC
rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (756/12) Bayer PLC 13 January 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationNORTH WEST LONDON GUIDANCE ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION
North West London CardioVascular & Stroke Network NORTH WEST LONDON GUIDANCE ON ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION Key Messages 1. Efforts should be made to identify patients with Atrial
More informationStacey Moultrie, PharmD ROCKET-AF 1. "Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation" 1
Stacey Moultrie, PharmD ROCKET-AF 1 I. Introduction: (1-4) "Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation" 1 ROCKET-AF: The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared
More information} Most common arrhythmia. } Incidence increases with age. } Anticoagulants approved for AF
Deniz Yavas, PharmD PGY-2 Ambulatory Care Pharmacy Resident Detroit Veterans Affairs Medical Center } Most common arrhythmia 0.4-1% of Americans (2.2 mil people) 1,2 } Incidence increases with age 6% (65
More informationWhat You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist
What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential
More informationAtrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationNovel OACs: How should we use them?"
Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationPractical everyday use of NOACs. Dr. Elisabetta Toso SOC Cardiologia Ospedale Cardinal Massaia - Asti
Practical everyday use of NOACs Dr. Elisabetta Toso SOC Cardiologia Ospedale Cardinal Massaia - Asti THE NEW ANTICOAGULANTS HISTORY Oral Inhibitors Edoxaban Apixaban Betrixaban EXPLORE-Xa Phase II trial
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationAnticoagulation Management Insanity: doing the same thing over and over again and expecting different results. Case 1
2011 MFMER slide-1 Anticoagulation Management Insanity: doing the same thing over and over again and expecting different results Fadi Elias Shamoun, MD Mayo Clinic in Arizona Albert Einstein Anticoagulation
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationNIL. Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts. Approach. Approach. 06-Nov-14
Stroke Prevention in Atrial Fibrillation: Commencing Non- Oral Anticoagulants in GP setting Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts Disclosures NIL Classification
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationAtrial Fibrillation Current State of Management with Importance to Newer Anticoagulants and Devices
Atrial Fibrillation Current State of Management with Importance to Newer Anticoagulants and Devices Garland Green, MD Interventional Cardiologist Cardiovascular Institute of the South Disclosures: Speaker
More information9/8/2014. None. Identify the under-recognized risk of cardioembolic stroke in untreated and undertreated. morbidity, mortality and cost burdens
Optimizing Anticoagulation Therapy for Older Adults with Atrial Fibrillation: The New Oral Agents" None Disclosures Brad Hein, PharmD Associate Professor of Pharmacy The University of Cincinnati Winkle
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationObjectives. Epidemiology. Pathophysiology 4/1/2013
Objectives The New CHEST Guidelines, The Bleeding War Continues Ginger Warren, PharmD., MCSR gwarren@valleyhealthlink.com PGY1 Pharmacy Resident Valley Health System/Bernard J Dunn School of Pharmacy,
More informationNovel Oral Anticoagulants and Warfarin Comparative evidence and Information for Prescribers
Novel Oral Anticoagulants and Warfarin Comparative evidence and Information for Prescribers How does it work? Dose and Administration Monitoring Warfarin Dabigatran Rivaroxaban Apixaban Warfarin has an
More informationStroke Prevention in Atrial Fibrillation. Dr. LEUNG Tat Chi Godwin Specialist in Cardiology
Stroke Prevention in Atrial Fibrillation Dr. LEUNG Tat Chi Godwin Specialist in Cardiology Objectives What is atrial fibrillation (AF)? Who gets AF? Why does AF cause stroke? What are the current therapeutic
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationPrevention of stroke in patients with atrial fibrillation
www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment
More informationRivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationCurrent and new oral Anti-coagulation. Lancashire and Cumbria Network 2 February 2012
Current and new oral Anti-coagulation Lancashire and Cumbria Network 2 February 2012 Question Warfarin is an abbreviation What does the W stand for? What is this plant and what is the connection with warfarin?
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationWhat s New in Stroke?
5 th McMaster University Review Course in INTERNAL MEDICINE What s New in Stroke? Robert Hart, M.D. HHS / McMaster Stroke Program Department of Medicine (Neurology) McMaster University Hamilton, Ontario
More informationCCPN SPAF Tool. www.ccpn.ca STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF): POCKET REFERENCE
SEPTEMBER 2013 CCPN SPAF Tool STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF): POCKET REFERENCE Approximately 20% of all strokes are attributable to Atrial Fibrillation (AF). 1 Of these, 20% will result
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationNew Anticoagulants. Stroke Prevention in AF Commencing Novel Oral Anticoagulants (NOACs) in the GP Setting. 30-Oct-14
Stroke Prevention in AF Commencing Novel Oral Anticoagulants (NOACs) in the GP Setting A/Prof Michael Nguyen Fremantle Hospital Access Cardiology General Practice Education Day Oct 2014 ORAL TTP889 Rivaroxaban
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationThe New Anticoagulants: Which one is for You?
The New Anticoagulants: Which one is for You? by Hans R. Larsen Although there is no evidence that otherwise healthy lone afibbers have an increased risk of ischemic stroke, it is clear that atrial fibrillation
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) Indication: Stroke Prevention in Atrial Fibrillation This recommendation supersedes the Canadian Drug Expert Committee (CDEC) recommendation for
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationTurn the Beat Around-Remix: Atrial Fibrillation Guidelines-2014 Updates
Turn the Beat Around-Remix: Atrial Fibrillation Guidelines-2014 Updates Brittany Karns, PharmD Alaska Pharmacists Association Annual Conference - 2015 Disclosures I have no actual or potential conflicts
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More information